![]() Namer B, Carr R, Johanek LM, Schmelz M, Handwerker HO, Ringkamp M. The itch-producing agents histamine and cowhage activate separate populations of primate spinothalamic tract neurons. 2017 158(9):1780-91.ĭavidson S, Zhang X, Yoon CH, Khasabov SG, Simone DA, Giesler GJ Jr. Non-histaminergic and mechanical itch sensitization in atopic dermatitis. 2010 34(2):171–6.Īndersen HH, Elberling J, Solvsten H, Yosipovitch G, Arendt-Nielsen L. ![]() Ikoma A, Steinhoff M, Stander S, Yosipovitch G, Schmelz M. Itch associated with skin disease: advances in pathophysiology and emerging therapies. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, et al. Skin surface pH, stratum corneum hydration, trans-epidermal water loss and skin roughness related to atopic eczema and skin dryness in a population of primary school children. 1991 283(4):219–23.Įberlein-Konig B, Schafer T, Huss-Marp J, Darsow U, Mohrenschlager M, Herbert O, et al. Stratum corneum lipid abnormalities in atopic dermatitis. Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. The impact of atopic dermatitis on quality of life. What causes itch in atopic dermatitis? Curr Allergy Asthma Rep. Quality of life in patients with atopic dermatitis: disease burden, measurement, and treatment benefit. Itch characteristics in atopic dermatitis: results of a web-based questionnaire. 2005 25(2):333–51.ĭawn A, Papoiu AD, Chan YH, Rapp SR, Rassette N, Yosipovitch G. Atopic dermatitis: beyond the itch that rashes. Finally, suggested therapeutic ladders and emerging treatments are discussed.īoguniewicz M. ![]() This review assesses the latest advances and treatment recommendations for pruritus in AD. Finally, patient education, sleep management, and stress relief are important components to optimize outcomes. There are multiple adjuvant therapies that can be used, especially to target itch in the setting of minimal skin inflammation. Step-wise therapy, from topical anti-inflammatory creams to systemic monoclonal antibodies and immunosuppressants, is recommended. Topical moisturizers remain the foundation of treatment and should be used by all patients with AD-associated pruritus. The optimal treatment regimen for atopic itch addresses barrier dysfunction, inflammation, neural hypersensitivity, and the itch–scratch cycle. Treating itch in AD has been challenging for decades, but new drugs have emerged in the last year with significant anti-pruritic effect. Chronic itch in this condition has significant impact on measures of quality of life, such as sleep. Atopic dermatitis (AD) is the most common itchy dermatosis that affects millions of children and adults worldwide. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |